Galapagos and Merck Serono Enter new Collaboration Agreements
News Nov 19, 2008
Galapagos NV announces new collaboration agreements with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. Total value of the contracts for Galapagos is €1.1 million over one year.
Galapagos’ service division BioFocus DPI will provide SoftFocus© compounds for use in Merck Serono’s drug discovery programs.
In a separate agreement, BioFocus DPI will perform medicinal chemistry services on an undisclosed Merck Serono program; this represents an extension of a long running collaboration which was last expanded in 2005.
“BioFocus DPI has a long relationship with Merck Serono in medicinal chemistry, which we are pleased to extend again this year,” said Onno van de Stolpe, CEO of Galapagos. “The purchase of BioFocus DPI’s SoftFocus libraries underscores our ability to grow business with clients.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE